PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

More ovarian cancer patients benefit from maintenance combined targeted therapy

Comment: Immunotherapy combination for advanced NSCLC

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA

Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezomib and dexamethasone

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history